Binding of galectin-3 by low molecular weight pectin
Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.
1. A method of treating a mammal which benefits from a reduction in available circulating galectin-3, comprising the steps of:
a) Selecting a mammal in need of at least one of inhibition or reduction of formation of fibroses, and
b) Administering to said mammal an amount of modified citrus pectin of molecular weight of 3,000-13,000 Daltons, in an amount of 10-750 mg/kg/day, for a period of time sufficient such that said mammal exhibits a reduction in active galectin-3 levels in said mammal and thereby inhibit in said mammal formation of fibroses or thereby reduce formation of fibroses in said mammal.
2. A method of treating a mammal which benefits from a reduction in available galectin-3, comprising the steps of:
a) Selecting a mammal in need of at least one of inhibition or reduction of the formation of fibroses, and
b) Administering to said mammal an amount of modified citrus pectin of low molecular weight of 10,000-20,000 Daltons, in an amount of 5-1,500 mg/kg/day, for a period of time sufficient for said mammal to exhibit a reduction in active galectin-3 levels in said mammal and thereby inhibit in said mammal formation of fibroses or thereby reduce formation of fibroses in said mammal.